• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Int J Infect Dis . Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - a ten-year (2012-2022) global analysis of human and camel infections,

tetano

Editor, Senior Moderator
Int J Infect Dis


. 2023 Mar 28;S1201-9712(23)00125-X.
doi: 10.1016/j.ijid.2023.03.046. Online ahead of print.
Middle East Respiratory Syndrome Coronavirus (MERS-CoV) - a ten-year (2012-2022) global analysis of human and camel infections, genomic sequences, lineages, and geographical origins


Esam I Azhar[SUP] 1 [/SUP], Thirumalaisamy P Velavan[SUP] 2 [/SUP], Ikrormi Rungsung[SUP] 3 [/SUP], Tieble Traore[SUP] 4 [/SUP], David S Hui[SUP] 5 [/SUP], Brian McCloskey[SUP] 6 [/SUP], Sherif A El-Kafrawy[SUP] 7 [/SUP], Alimuddin Zumla[SUP] 8 [/SUP]



Affiliations

Abstract

Background: The WHO priority zoonotic pathogen MERS-CoV has a high case fatality rate in humans and circulates in camels worldwide.
Methods: We performed a global analysis of human and camel MERS-CoV infections, epidemiology, genomic sequences, clades, lineages and geographical origins for the period January 1st, 2012, to August 3rd, 2022. MERS-CoV 'S'-gene sequences (4061bp) were extracted from Genebanks, and a phylogenetic maximum likelihood tree constructed.
Findings: As of August 2022, 2591 human MERS cases from 26 countries were reported to the WHO (Saudi Arabia, 2184 cases, including 813 deaths (CFR:37.2%) Whilst declining in numbers, MERS cases continue to be reported from the Middle East. 728 MERS-CoV genomes identified (the largest number were from Saudi Arabia:222:human=146, camels=76) and UAE(176:human=21,camels=155). 501 'S'-gene sequences were used for phylogenetic tree construction [camels(n=264), humans(n=226), bats(n=8), other(n=3)]. Three MERS-CoV Clades were identified: the largest, Clade B, followed by clade A and clade C. Of 462 Clade B lineages, lineage 5 was predominant,(n=177).
Interpretation: MERS-CoV remains a threat to global health security. MERS-CoV variants continue circulating in humans and camels. Recombination rates indicate co-infections with different MERS-CoV lineages. Proactive surveillance of MERS-CoV infections and variants of concern in camels and humans worldwide is essential for epidemic preparedness.
 
Back
Top